Subtype
Malignant Colorectal Neoplasm
CI-CAN-00005874Explore in graph →
1,565 active trials21 approved drugs382 evidence items
- NCIt
- C4978
- DOID
- 9256
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005874Explore in graph →
Clinical trials
7,296 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (722)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04516681 | Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer | recruiting | Phase 3 | 400 | Fudan UniversityOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT06653452 | Application of PET/MRI in the Evaluation of the Efficacy of Neoadjuvant Therapy for Locally Advanced Rectal Cancer | recruiting | N/A | 30 | Peking Union Medical College HospitalOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT06653478 | Development and Demonstration of Intelligent Assessment Based on Multi-modal Information Fusion for Tumor Risk and Diagnosis and Treatment | recruiting | — | 3,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT03635021 | Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer(CR-SEQUENCE) | active not recruiting | Phase 3 | 419 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT06207656 | Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer(CEBBRA) | recruiting | Phase 2 | 70 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT02579278 | Circulating Tumour DNA (ctDNA) in Patients With Colorectal Cancer and the Relationship to Imaging Features of Extramural Venous Invasion(ctDNA) | recruiting | — | 100 | Imperial College LondonOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT02704520 | Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial(TRIGGER) | recruiting | N/A | 441 | Imperial College LondonOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT03303547 | Concordance of Imaging and Pathology Diagnosis of Extranodal Tumour Deposits(COMET) | recruiting | N/A | 200 | Imperial College LondonOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04547166 | A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC) | recruiting | Phase 2 / Phase 3 | 568 | Shanghai Henlius BiotechINDUSTRY | 2 | Oct 17, 2024 | clinicaltrials |
| NCT06275958 | DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer(DOSAGE) | recruiting | Phase 3 | 587 | Leiden University Medical CenterOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06633133 | Virtual Ileostomy Versus Diverting Ileostomy in Patients Undergoing Total Mesorectal Excision | recruiting | N/A | 620 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06643429 | Impact of Environmental Factors and Metabolomics on Colorectal Cancer. | active not recruiting | — | 700 | Dong PengOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06645301 | BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies | not yet recruiting | Early Phase 1 | 15 | BioSyngen Pte LtdINDUSTRY | 0 | Oct 16, 2024 | clinicaltrials |
| NCT04584008 | Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics(VISIONARY) | active not recruiting | N/A | 600 | Peking UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05250648 | Clinical Trial on HIPEC With Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)(GECOP-MMC) | recruiting | Phase 4 | 216 | Hospital Universitario de FuenlabradaOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT05955196 | Test of CD47-SIRPα Inhibitors on the Immune Microenvironment Colon Cancer(MACROSWITCH) | recruiting | — | 115 | Institut Paoli-CalmettesOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06184698 | Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer | recruiting | Phase 2 | 173 | Hebei Medical University Fourth HospitalOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06632886 | AI-Assisted Non-Contrast CT for Multi-Cancer Screening | recruiting | N/A | 1,000,000 | Guo ShiWeiOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06220045 | Comparing PP and PVDF Meshes in Midline Laparotomy Closure for High-risk Colorectal Surgery. Impact on Incisional Hernia and Surgical Wound Infection.(PROFIMESH) | recruiting | N/A | 60 | Institut d'Investigació Biomèdica de Girona Dr. Josep TruetaOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06220058 | Comparing Polypropylene Mesh and "Small Bites" Technique in Emergency Colorectal Surgery's Midline Laparotomy Closure. Study for Incisional Hernia Prevention.(BITEME) | recruiting | N/A | 148 | Fernandez ZamoraOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06452745 | Early Diagnosis of Colorectal Cancer Based on a Non-invasive Metabolomics Profile(EarlyCRC) | recruiting | — | 2,000 | Institut Investigacio Sanitaria Pere VirgiliOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT05628038 | The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer(TORCH-R) | recruiting | Phase 2 | 93 | Fudan UniversityOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06619886 | TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor | not yet recruiting | Early Phase 1 | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04117945 | Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer | active not recruiting | Phase 2 | 22 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06614660 | Metabolism Imaging-genomics for Predicting the Surgical Outcomes of Colorectal Cancer | active not recruiting | — | 800 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06614699 | Predictive Effect of Abdominal Fat and Muscle Area Calculated Based on Abdominal CT on Colorectal Cancer Patients | active not recruiting | — | 8,000 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06614751 | A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway | not yet recruiting | Phase 1 | 112 | Danatlas Pharmaceuticals Co., LtdINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06616259 | First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study(CAPCET-III) | not yet recruiting | Phase 3 | 452 | Meng QiuOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06616870 | Study of the Predictive and Prognostic Role of Pharmacogenetic and Radiogenic Variants on the Response to Neoadjuvant Chemoradiation Therapy in Patients With Locally Advanced Rectal Cancer(IGLarc) | not yet recruiting | — | 460 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06613399 | Multi-Technology Integrated Total Mesorectal Excision Versus Conventional Total Mesorectal Excision for the Treatment of Middle and Distal Rectal Cancer. | not yet recruiting | N/A | 324 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Sep 26, 2024 | clinicaltrials |
| NCT06613581 | Patient-led Follow-up from Home After Surgery for Colorectal Carcinoma(PROMISE) | recruiting | N/A | 200 | Erasmus Medical CenterOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT05656326 | Follow-up After Surgery for Colorectal Cancer(FUTURE-primary) | active not recruiting | — | 200 | Erasmus Medical CenterOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06259552 | A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors(SPX-303) | recruiting | Phase 1 | 232 | SparX Biotech(Jiangsu) Co., Ltd.OTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT06609551 | ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study(ZJCH-CRCC-1) | recruiting | Phase 3 | 312 | Zhejiang Cancer HospitalOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT06606912 | Predictive Effect of Abdominal Fat and Muscle Area Calculated Based on Abdominal CT on Gastric Cancer Patients | active not recruiting | — | 4,000 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT05961969 | Robotic Top-down Intersphincteric Resection | recruiting | — | 40 | National Taiwan University HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT05964530 | Radical vs Local Excision for Rectal Cancer With Clinically Complete Remission | recruiting | N/A | 180 | National Taiwan University HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT05970133 | Robotic Versus Laparoscopy NOSE for Stage I-III Left-sided Colon Cancer | recruiting | N/A | 300 | National Taiwan University HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT02919644 | Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.(COREVAX-1) | recruiting | Phase 2 | 19 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03779009 | Minimally INvasive Colon Cancer Surgery Through IMmunomics and Optical Mapping of the Sentinel Lymph Node.(MINIMAL) | recruiting | N/A | 70 | University Hospital, GhentOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05168839 | Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage(FLUOCOL-1) | recruiting | Phase 3 | 1,010 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06493760 | A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients | recruiting | Phase 2 | 130 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06540261 | The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer | active not recruiting | Phase 1 | 65 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06589388 | ctDNA Monitoring to Predict the Efficacy of TNT for Rectal Cancer | recruiting | — | 100 | Gene SolutionsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06593548 | Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer | not yet recruiting | Phase 2 | 36 | Fudan UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06594692 | Node-Sparing Short-Course Radiation With CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer: A Randomized, Prospective, Multicenter Study(mRCAT-C) | not yet recruiting | Phase 2 | 140 | Sir Run Run Shaw HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06596343 | Evaluating the Benefits of Personalized Traditional Chinese Medicine in Postoperative Treatment for Locally Advanced Colorectal Cancer | not yet recruiting | Phase 2 | 80 | Sir Run Run Shaw HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06599827 | Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC(iMHRT-LARC) | not yet recruiting | Phase 2 | 54 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Oct 24, 2024source: clinicaltrials